DSM-Firmenich completes buyback. DSM-Firmenich stock sits 0.40 percent below its high
Published on 10/12/2026 at 09:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- DSM-Firmenich completed its EUR 540.00 million share repurchase program on October 1, 2026.
- The company plans to cancel 6,488,446 shares by the end of the first quarter of 2027.
- The stock was trading at EUR 100.10 at Lang & Schwarz on October 12, 2026, below its EUR 100.50 52-week high.
- An extraordinary shareholders meeting is scheduled for October 19, 2026.
DSM-Firmenich (ISIN CH1216478797) was trading at EUR 100.10 at Lang & Schwarz on October 12, 2026 at 9:05 a.m. CEST, 0.40 percent below its EUR 100.50 52-week high. The company completed a EUR 540.00 million share repurchase program on October 1, 2026, giving the stock a concrete capital-allocation event to weigh alongside its recent results.
Three dated steps shape the story
On July 30, 2026, DSM-Firmenich reported first-half revenue of EUR 4.664 billion from continuing operations and adjusted EBITDA of EUR 900.00 million, according to De Belegger. Like-for-like revenue growth reached 5.00 percent in the first half, while reported revenue was nearly unchanged from the prior year.
On September 29, 2026, the company had reported EUR 520.90 million of cumulative repurchases, including 6,976,047 shares, in a release carried by GlobeNewswire. On October 1, the final total reached EUR 540.00 million and 7,169,147 shares, making the latest announcement the decisive capital event in the recent timeline.
What the buyback changes
GlobeNewswire reported on October 1, 2026 that DSM-Firmenich intends to cancel 6,488,446 shares by the end of the first quarter of 2027. The planned reduction would take issued shares from 253,626,947 to 247,138,501, a direct change to the capital base rather than a new operating forecast.
The operating counterweight is execution. First-half adjusted EBITDA of EUR 900.00 million was below the EUR 906.00 million reported for the comparable period in the cited analysis, even though adjusted EBITDA grew 7.00 percent on a like-for-like basis. The company also targeted an adjusted EBITDA margin of 20.00 percent for fiscal 2026, making cash generation and margin delivery important tests for the valuation.
Dates investors can measure
DSM-Firmenich is scheduled to hold an extraordinary shareholders meeting on October 19, 2026, according to VZ. The next reporting date is listed as February 18, 2027 by Simply Wall St.
Stock remains near its yearly high
At EUR 100.10, the Lang & Schwarz quote stood EUR 0.40 below the EUR 100.50 52-week high on October 12, 2026. The stock therefore enters the October 19 meeting with the buyback completed, a planned share cancellation ahead and the market price close to the top of its latest annual range.
The further course of trading is shown by the continuously updated real-time quote of DSM-Firmenich stock.
DSM-Firmenich stock facts
- Company: DSM-Firmenich AG
- ISIN: CH1216478797
- Ticker: DSFIR
- Primary exchange: Euronext Amsterdam
- Price Lang & Schwarz (as of October 12, 2026, 9:05 a.m. CEST): EUR 100.10
- 52-week range: EUR 55.22-100.75 (as of October 9, 2026)
- Market capitalization: EUR 24.8 billion (as of October 9, 2026)
- Sector: Materials
- Index membership: SMIM
- Next earnings date: February 18, 2027
Market context: Market report AEX.
